Unis short sale restriction, page-48

Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers

The esclusivity is not for all W.I.S but in certain classes of drugs, so for instance Sanofi will continue with their contract . Whether Amgen got all other areas or just some we do not know